Company Overview
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.24.
Recent Developments
- Dec 2025 Revenue of $16.96M (-16.1% YoY); net profit $-23.88M.
- Trailing 12 Months Year-on-year growth — revenue -45.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -13.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -13.82% |
| 1 Year: | -45.80% |
Stock Price Performance
| 1 Year: | -36.00% |
| 6 Months: | -28.23% |
| 3 Months: | -16.96% |
| 1 Month: | -13.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -13.8% CAGR over 5 years.
- Trading 39.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDWD MediWound Ltd. R2KR3KPHARMA | 12.00 | -5.56 | $154.92M | 0.00% | -41.75% | -72.37% | -13.82% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 3.96M | 5.71M | 5.43M | 1.87M | 1.48M |
| Cost of Revenue | - | 3.22M | 4.37M | 4.53M | 1.59M | 1.15M |
| Gross Profit | - | 738.00K | 1.34M | 896.00K | 278.00K | 323.00K |
| Operating Expenses | - | 5.96M | 7.06M | 7.42M | 8.09M | 8.30M |
| Operating Income | - | -5.22M | -5.72M | -6.53M | -7.81M | -7.98M |
| EBITDA | - | -4.87M | -5.32M | -6.11M | -5.17M | -7.60M |
| Interest Expense | - | - | 7.56M | - | - | - |
| Pretax Income | - | -721.00K | -13.28M | -2.60M | -7.11M | -2.97M |
| Tax Provision | - | 5.00K | 38.00K | 53.00K | 73.00K | -17.00K |
| Net Income | - | -726.00K | -13.32M | -2.65M | -7.18M | -2.95M |
| Diluted EPS | - | -0.07 | -1.23 | -0.24 | -0.56 | -0.23 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 26.50M | 18.69M | 20.22M | 16.96M |
| Cost of Revenue | - | 13.33M | 15.11M | 17.59M | 13.71M |
| Gross Profit | - | 13.16M | 3.58M | 2.63M | 3.25M |
| Operating Expenses | - | 20.83M | 19.08M | 22.02M | 28.53M |
| Operating Income | - | -7.66M | -15.50M | -19.38M | -25.28M |
| EBITDA | - | -18.25M | -4.80M | -27.93M | -21.47M |
| Interest Expense | - | 0 | 427.00K | 752.00K | 380.00K |
| Pretax Income | - | -19.52M | -6.53M | -30.16M | -23.71M |
| Tax Provision | - | 78.00K | 185.00K | 61.00K | 169.00K |
| Net Income | - | -19.60M | -6.72M | -30.22M | -23.88M |
| Diluted EPS | - | -3.93 | -0.75 | -3.03 | -2.10 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 50.02M | 66.46M | 73.50M | 86.25M |
| Current Assets | - | 45.84M | 49.70M | 52.16M | 59.96M |
| Cash & Equivalents | - | 33.90M | 11.87M | 9.15M | 4.80M |
| Inventory | - | 1.96M | 2.85M | 2.69M | 4.09M |
| Receivables | - | 9.33M | 3.70M | 4.80M | 1.62M |
| Total Liabilities | - | 39.10M | 34.86M | 42.34M | 42.62M |
| Current Liabilities | - | 12.06M | 18.12M | 26.54M | 25.71M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 846.00K | 6.35M | 6.51M | 8.15M |
| Total Equity | - | 10.91M | 31.59M | 31.15M | 43.63M |
| Shares Outstanding | - | 7.24M | 9.22M | 10.79M | 12.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -11.88M | -10.46M | -13.62M | -16.12M |
| Investing Cash Flow | - | -481.00K | -34.32M | -8.40M | -17.95M |
| Financing Cash Flow | - | 35.76M | 22.92M | 19.39M | 29.62M |
| Capital Expenditure | - | -555.00K | -6.46M | -6.27M | -5.50M |
| Free Cash Flow | - | -12.44M | -16.93M | -19.90M | -21.63M |
| Net Change in Cash | - | 23.40M | -21.87M | -2.63M | -4.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 49.7% | 19.1% | 13.0% | 19.2% |
| Operating Margin % | - | -28.9% | -83.0% | -95.8% | -149.1% |
| Net Margin % | - | -74.0% | -35.9% | -149.5% | -140.8% |
| ROE % | - | -179.6% | -21.3% | -97.0% | -54.7% |
| ROCE % | - | -20.2% | -32.1% | -41.3% | -41.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Investor AB | 6.83% | 872.09K | $10.94M |
| 2 | Yelin Lapidot Holdings Management Ltd. | 5.94% | 758.17K | $9.51M |
| 3 | Rosalind Advisors, Inc. | 5.87% | 749.05K | $9.39M |
| 4 | Price (T.Rowe) Associates Inc | 5.02% | 641.08K | $8.04M |
| 5 | Blackrock Inc. | 4.12% | 525.93K | $6.60M |
| 6 | Sphera Funds Management Ltd. | 2.14% | 273.19K | $3.43M |
| 7 | Silverberg Bernstein Capital Management LLC | 1.79% | 228.14K | $2.86M |
| 8 | State Street Corporation | 1.32% | 168.67K | $2.12M |
| 9 | UBS Group AG | 1.22% | 155.92K | $1.96M |
| 10 | Geode Capital Management, LLC | 1.11% | 141.04K | $1.77M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDWD
MediWound Ltd. Estimates – NASDAQ:MDWD - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBhTXVHek13bV9ONUd6Wm8yTVFrbWhheFA3R3JvSFlVQ0VPbDBoTXhsSndvTzNvSFN0ZHVTYUZNbVhEeDBETGFtM1JjUE8yTjljZjFLekFRZmxiRHozWlJnbV8wSlVDMUxDbDVSdktqbUNSN3pqNXNYYg?oc=5" target="_blank">MediW…
(MDWD) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbnN1MkJBNDRkQk5aYUYzWGpqaDc2QTNBN1hJVHJqbm5veHJVMFhGak1SRXhPTWF6Z0puMFB3NGdCWUJ6Nm5lTXNGUHJYaWlYNk9qdElXQkZ0ZmdXaVY4X3JveFhGdkZnQjJPMkRYZ2Y2RkZOTGQ0T3lmYUNLRjY4MktQLTNqVy1HSVRrSE…
MDWD Nov 2026 15.000 call (MDWD261120C00015000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE1uQjNiaEtySU02UUloZkkyVnZKelRVdlJwNFZUS0puUHR2YUZ2eXdGN3ktSGtUcUt0cnp0RnBuY1VHVGJ2RUh6YzNoVWloLW8wR0gtZlhfY1ZZRDRzVEpzQk1wRW1RQQ?oc=5" target="_blank">MDWD Nov 2026 15.000 call (MD…
MediWound (MDWD) Stock Faces Cash Burn As Revenue Slips - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQU2g5NlcwZnhWcU42S1FQbG5kVDZiT09KaDRyY0FGdzUtVUpNdFpwa251TzF4ZGVaRk91cVVzOHh5UUJqdTVBb2htQVdTRE53Qm1JeVM4dlYzMFZ0VVdSUDhiYzUyc3JabFVvNTU0bGR4TE9CYzlVZ1lBTW9xMm5QUnlRck5YSEJHWS00el…
MEDIWOUND ($MDWD) Releases Q2 2026 Earnings | MDWD Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNTHdhWGRuZi00bjJGRHJiQTRlaXAwVG5FVDl6dlVWYVFzSkluT3J6al9iaWRzaXBrY0FIc2VIc0czbUozU2RqT19MN3RvVzd3RTcyTmZ3QjR5UUxBc1RXTlVYa1A5Vmk0aGF1ajQzanNGX29QS1I1cnZLV2pPaklGUV9R?oc=5" target=…
MDWD Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1mcTEzOTVVeFJTR1BvLW5Hd1VXOEdkaEl6bkt2NklrUk1BbWdDX0ZQVTJvQkpWNklzWEdEb0x1WmVlX0gwTkNvUkF1bWIta2M2Rm1QbmhpcTVzZEZuLU9jRDFpMFRHUEJxZTE0ajRiSmhmcWwxSDMwN0d3?oc=5" target="_blank">MDW…
MDWD — Frequently Asked Questions
What is the current share price of MediWound Ltd. (MDWD)?
As of 2026-10-23 16:27 PDT, MediWound Ltd. (MDWD) trades at $12.00 on NasdaqGM. Its 52-week range is $11.85 to $19.69.
What is the market capitalisation of MDWD?
MediWound Ltd. (MDWD) has a market capitalisation of $154.92M on NasdaqGM.
What is the P/E ratio of MDWD?
MDWD trades at a trailing price-to-earnings (P/E) ratio of -5.56. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 4.85.
What is the return on equity (ROE) of MDWD?
MDWD has a return on equity (ROE) of -72.37%. Its return on capital employed (ROCE) is -41.75%.
Is MDWD a good stock to buy?
This page provides a data-driven analysis of MediWound Ltd. (MDWD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.